Global Non-Hodgkin Lymphoma (NHL) Therapeutics Markets, Competition Forecast & Opportunities to 2026 - ResearchAndMarkets.com

Posted 9/28/21

DUBLIN--(BUSINESS WIRE)--Sep 28, 2021--

The report has been added to ResearchAndMarkets.com's offering.

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is expected to reach …

To Our Valued Readers –

Visitors to our website will be limited to five stories per month unless they opt to subscribe. The five stories do not include our exclusive content written by our journalists.

For $5.99, less than 20 cents a day, digital subscribers will receive unlimited access to YourValley.net, including exclusive content from our newsroom and access to our Daily Independent e-edition.

Our commitment to balanced, fair reporting and local coverage provides insight and perspective not found anywhere else.

Your financial commitment will help to preserve the kind of honest journalism produced by our reporters and editors. We trust you agree that independent journalism is an essential component of our democracy. Please click here to subscribe.

Sincerely,
Charlene Bisson, Publisher, Independent Newsmedia

Please log in to continue

Log in
I am anchor

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Markets, Competition Forecast & Opportunities to 2026 - ResearchAndMarkets.com

Posted

DUBLIN--(BUSINESS WIRE)--Sep 28, 2021--

The report has been added to ResearchAndMarkets.com's offering.

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is expected to reach USD14689.31 million in 2026, growing at a CAGR of 10.02% owing to increasing demand for innovative drugs and novel technologies for the treatment of Non-Hodgkin's lymphomas (NHL).

Improved diagnostic techniques to detect NHL are expected to push the demand for Non-Hodgkin Lymphoma (NHL) market. Furthermore, patent expiry of standard drugs, especially in untapped market is projected to provide profitable growth opportunities for the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in upcoming years. Also, extensive R&D activities and the US Food and Drug Administration's approval for chronic lymphocytic leukemia therapy drugs are serving as major growth drivers for the market.

Non-Hodgkin's lymphoma (NHL) is a type of blood cancer that originates in white blood cells called lymphocytes, which are part of the body's immune system. It is generally located at lymph nodes but if not treated on time, it might spread to the entire lymphatic system.

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market can be segmented based on type of therapy, cell type, drug type, distribution channel, company and region. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Out of which, hospital pharmacies held the largest market share in 2020 and is estimated to maintain its leading position in the market in the next five years as well, because these therapeutic drugs are mostly dispensed in hospital pharmacies for the hospitalized patients in order to treat them. In terms of cell type, the market is fragmented into B-cell Lymphomas and T-cell Lymphomas.

B-cell Lymphomas is the dominant cell type which can be attributed to the fact that B-cell Lymphomas accounts for the majority of Non-Hodgkin Lymphoma cases across the globe. On the other hand, there are smaller number of patients with T-cell Lymphoma as compared to B-cell Lymphomas.

Regionally, North America dominated the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in 2020 and is further expected to hold its dominance during the forecast period. High prevalence of Non-Hodgkin lymphoma (NHL) and availability of advanced treatments in the region are acting as key growth drivers for the market. However, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period owing to rising awareness and prevalence of Non-Hodgkin lymphoma (NHL) in the region.

The market players are focusing on R&D activities to enhance their product portfolios and strengthen their position in global market. Besides, large pharmaceutical companies are adopting strategies such as collaborations and acquisitions to further bolster their status in the Non-Hodgkin's lymphoma therapeutics market. Also, strong product pipeline of the top players operating in the market, launch of new therapies along with commercialization of new products are other factors which are further expected to drive growth in the forthcoming years.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Non-Hodgkin Lymphoma (NHL) therapeutics market.

Major companies operating in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market include

Report Scope:

Years considered for this report:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Cell Type:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Drug Type:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Distribution Channel:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Region:

For more information about this report visit

View source version on businesswire.com:

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 09/28/2021 06:20 AM/DISC: 09/28/2021 06:21 AM

http://www.businesswire.com/news/home/20210928005573/en

Comments